Biologicals, including vaccines, monoclonal antibodies (mAbs) and recombinant proteins, have been produced at large scale for decades with established production methods. However, emerging modalities and next generation biotherapeutics require innovative methods and technologies to support and enable their robust, reproducible, safe, efficient, and economic production at scale.